Effects of Clodronate and Antioestrogens on Bone Loss in Postmenopausal Women with Breast Cancer
Author Information
Author(s): Saarto T, Vehmanen L, Elomaa I, Välimäki M, Mäkelä P, Blomqvist C
Primary Institution: Helsinki University Central Hospital
Hypothesis
Do postmenopausal women who have recently discontinued hormone replacement therapy experience different bone mineral density changes compared to those who have not used it?
Conclusion
Postmenopausal women who recently stopped hormone replacement therapy experience more rapid bone loss than those who did not use it.
Supporting Evidence
- Women who recently used hormone replacement therapy had a significant bone loss of 3.0% in lumbar spine after 3 years.
- Clodronate treatment improved bone mineral density in lumbar spine by 1.0% after 3 years.
Takeaway
Women who stop taking hormone therapy lose bone faster than those who never took it, even with treatment.
Methodology
61 postmenopausal women were treated with antioestrogens and randomized to receive clodronate or control for 3 years, with bone mineral density measured at multiple time points.
Potential Biases
Potential selection bias in the randomization process.
Limitations
The study may not account for all variables affecting bone density changes.
Participant Demographics
Postmenopausal women with operable breast cancer.
Statistical Information
P-Value
P< 0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website